Acer Therapeutics announced data was presented from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders at the 44th Annual Meeting of the Society for Inherited Metabolic Disorders , March 18th-21st in Salt Lake City, Utah. Results from the discrete choice experiment presented showed that taste and odor were the most important attributes, as identified by UCD healthcare providers, that influence overall prescription of, and patient adherence to, UCD treatments when evaluating nitrogen-binding medications. "Nitrogen-binding medications, such as sodium phenylbutyrate or glycerol phenylbutyrate, can be efficacious in the treatment of UCDs if patients are adherent to their prescribed treatment1,2," stated Robert Steiner, M.D., Professor at the University of Wisconsin School of Medicine and Public Health. "However, 25% of life-threatening hyperammonemic crises in patients with UCDs may be precipitated by a lack of adherence to medications and/or diet and certain attributes of existing nitrogen-binding medications may negatively impact adherence3. Given these results, alternative treatment options are urgently needed."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACER:
- Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes
- Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biotech Alert: Searches spiking for these stocks today
- Acer Therapeutics Plummets on Pausing ACER-801 Trial
- Acer reports Phase 2 trial of ACER-801 did not achieve statistical significance
